Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated January 2, 2025, serves as a notification to the market regarding the company's issued share capital and total voting rights as of December 31, 2024. The filing is made in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure details:
- Issued Share Capital: 4,314,303,734 Ordinary Shares of 31 1/4 pence each.
- Treasury Shares: 169,171,155 Ordinary Shares held in Treasury.
- Total Voting Rights: 4,145,132,579.
Material Changes
The filing text does not provide comparative data against prior periods to identify material changes in share capital or voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. Its sole purpose is to provide the denominator for shareholder calculations regarding notification requirements under FCA rules.
Investor Verification Checklist
- Verify the total number of voting rights (4,145,132,579) for compliance with FCA disclosure thresholds.
- Confirm the number of shares held in Treasury (169,171,155) when calculating net outstanding shares.
- Ensure the share price of 31 1/4 pence per Ordinary Share is used for capital value calculations if required.